



**UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark Office**

ASSISTANT SECRETARY AND COMMISSIONER  
OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

November 19, 1986

Mr. Ronald Wilson  
Office of the Associate Commissioner  
for Health Affairs (HFY-20)  
Room 11-46  
Food and Drug Administration  
5600 Fishers Lane  
Rockville, MD 20857

RE: Buspar  
FDA Docket # 86E-0456

#15

Dear Mr. Wilson:

Transmitted herewith is a copy of the application for Patent Extension of U.S. Patent No. 4,182,763 issued January 8, 1981. The application was filed on October 27, 1986 under Title II of Public Law 98-417, the Drug Price Competition and Patent Term Restoration Act of 1984.

The patent claims a method of using a product that was subject to regulatory review under the Federal Food, Drug and Cosmetic Act. Subject to final review, the subject patent is considered to be eligible for patent term restoration. Thus, a determination of the applicable regulatory review period is necessary. Accordingly, notice and a copy of the application are provided pursuant to 35 USC 156(d)(2)(A).

*C. E. Van Horn*

Charles E. Van Horn  
Director, Group 120  
U.S. Patent and Trademark Office

cc: Isaac Jarkovsky, Esq.  
Assistant General Counsel - Patents  
Bristol-Myers Company  
345 Park Avenue  
New York, NY 10154